With just a few short weeks left until August recess, there is no shortage of items on the congressional to-do list. The latest round of Supreme Court decisions has inspired new action within Congress to pass legislation...more
7/8/2022
/ BsUFA ,
Centers for Medicare & Medicaid Services (CMS) ,
Children's Health Insurance Program (CHIP) ,
Department of Health and Human Services (HHS) ,
Department of Labor (DOL) ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
GDUFA ,
HELP ,
Infrastructure ,
Medicaid ,
Medical Device User Fee Program (MDUFA IV) ,
PDUFA ,
Proposed Legislation ,
Public Health Emergency ,
SCOTUS ,
Surprise Medical Bills ,
U.S. Treasury ,
User Fees
Here are some key health care policy headlines from the past week that you may have missed.
Congress -
Legislation and Committee Activity -
Bloomberg: Opioids Compromise Already in the Works in Congress – Congress is...more
9/27/2018
/ Acts of Congress ,
Centers for Medicare & Medicaid Services (CMS) ,
Continuing Resolution ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Gag Clauses ,
HELP ,
OMB ,
Opioid ,
Prescription Drugs ,
Proposed Rules ,
Regulatory Agenda ,
Telemedicine ,
Trump Administration
Congress is back in session after the August recess and, as expected, a flurry of activity took place. Here are some key health care policy headlines from the past week that you may have missed....more
9/13/2018
/ Acts of Congress ,
Affordable Care Act ,
Drug Pricing ,
HELP ,
HRSA ,
Opioid ,
Pharmacy Benefit Manager (PBM) ,
Primary Elections ,
Regulatory Agenda ,
Section 340B ,
Trump Administration
Foley & Lardner LLP’s Bipartisan Public Policy Team is pleased to share this week’s “Public Policy Health Care Newsletter” in which we compile the latest health care policy news and legislation. Please note that the next...more
7/30/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
GAO ,
Health Insurance ,
Healthcare Reform ,
HELP ,
Legislative Agendas ,
Medicare ,
Medicare Part D ,
MIPS ,
National Institute of Health (NIH) ,
Opioid ,
Prescription Drugs ,
Section 340B ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health Care policy news and legislation. *Please note that we...more
7/24/2018
/ Appropriations Bill ,
Biosimilars ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Federal Budget ,
Food and Drug Administration (FDA) ,
Healthcare ,
Healthcare Reform ,
Legislative Agendas ,
Legislative Committees ,
Medicaid ,
Medicare ,
Medicare Access and CHIP Reauthorization (MACRA) ,
Opioid ,
Secretary of HHS ,
Stark Law ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health care policy news and legislation. *Please note that we...more
7/2/2018
/ Appropriations Bill ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
FDA Approval ,
Food and Drug Administration (FDA) ,
Healthcare ,
Healthcare Fraud ,
HELP ,
Legislative Agendas ,
Medicaid ,
Medicare ,
New Legislation ,
Opioid ,
Pharmaceutical Industry ,
Proposed Legislation ,
Section 340B ,
Senate Finance Committee ,
Substance Abuse ,
Trump Administration ,
Veterans Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health care policy news and legislation. *Please note that we...more
6/26/2018
/ Affordable Care Act ,
Agency Consolidation ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Federal Funding ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Healthcare Reform ,
HELP ,
Legislative Agendas ,
Medicaid ,
Medicare ,
Opioid ,
Prescription Drugs ,
SAMHSA ,
Stark Law ,
State and Local Government ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health care policy news and legislation. *Please note that we...more
6/21/2018
/ Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Healthcare ,
HELP ,
Hospitals ,
Medicaid ,
Medicare ,
National Institute of Health (NIH) ,
Opioid ,
Pharmaceutical Industry ,
Proposed Legislation ,
Secretary of HHS ,
Senate Finance Committee ,
Substance Abuse ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly Health Care Newsletter” in which we compile the latest health care policy news and legislation.*Please note that we...more
5/21/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Federal Funding ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Healthcare Reform ,
HELP ,
Legislative Agendas ,
Medicaid ,
Medicare ,
Opioid ,
Prescription Drugs ,
Section 340B ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our second “Public Policy Weekly* Health Care Newsletter” in which we compile the latest health care policy news and legislation.
Please...more
5/14/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Children's Health Insurance Program (CHIP) ,
DEA ,
Department of Health and Human Services (HHS) ,
Department of Veterans Affairs ,
Drug Pricing ,
Federal Food Drug and Cosmetic Act (FFDCA) ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Health Insurance ,
Health Insurance Portability and Accountability Act (HIPAA) ,
Healthcare ,
Healthcare Reform ,
Legislative Agendas ,
Medicaid ,
Medicare Part C ,
Mental Health ,
National Institute of Health (NIH) ,
Pharmaceutical Industry ,
Prescription Drugs ,
Regulatory Agenda ,
Section 340B ,
Social Security Act ,
Trade Policy ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to introduce “This Week in Health Care Policy,” a new weekly publication providing a compilation of the latest health care policy news and legislation....more
5/1/2018
/ Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Department of Veterans Affairs ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Information Technology ,
Legislative Agendas ,
Opioid ,
Pharmaceutical Industry ,
Physicians ,
Prescription Drugs ,
Section 340B ,
Telemedicine
President-elect Trump and congressional Republicans have promised to “repeal and replace” the Affordable Care Act (ACA), but there is deep division regarding which provisions will be rescinded and around the details of the...more
1/20/2017
/ Affordable Care Act ,
Budget Reconciliation ,
Children's Health Insurance Program (CHIP) ,
Drug Pricing ,
Health Insurance ,
Insurance Industry ,
Legislative Agendas ,
Lobbying ,
Political Appointments ,
Repeal ,
Secretary of HHS ,
Senate Committees ,
Trump Administration